Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Episcleral Dexamethasone in Refractory Diabetic Macular Edema
NCT04005430Phase 1Active, not recruiting
- Sponsor
- Targeted Therapy Technologies
- Start
- Apr 2019
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dexamethasone in diabetic macular edema (DME), sponsored by Targeted Therapy Technologies. Primary endpoint: Safety assessment at 12 Months. Started Apr 2019; status: active, not recruiting.
02
Drugs
dexamethasone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04005430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005430.